tiprankstipranks
Trending News
More News >
Marwyn Value Investors Ltd (GB:MVI)
LSE:MVI
UK Market

Marwyn Value Investors (MVI) AI Stock Analysis

Compare
6 Followers

Top Page

GB:MVI

Marwyn Value Investors

(LSE:MVI)

Select Model
Select Model
Select Model
Outperform 82 (OpenAI - 5.2)
Rating:82Outperform
Price Target:
161.00 p
▲(20.15% Upside)
Action:N/ADate:01/04/26
The score is driven primarily by a very strong, low-debt balance sheet and solid cash generation, supported by an attractive valuation (low P/E and high dividend yield). Technicals are constructive with price above key moving averages and positive MACD, while the main risk remains volatility in revenue and earnings.

Marwyn Value Investors (MVI) vs. iShares MSCI United Kingdom ETF (EWC)

Marwyn Value Investors Business Overview & Revenue Model

Company DescriptionMarwyn Value Investors Limited specializes in investments in growth capital, buyout, industry consolidation, and acquisition-led growth strategies in small and mid-cap businesses. The fund also invests in consolidation opportunities in industry sectors that are undergoing structural or regulatory change, and is sector agnostic. It follows the buy-and-build strategy. It invests in companies based in Europe with a focus on the United Kingdom and North America. The fund seeks to invest in companies with enterprise value of EUR150 million ($158.11 million) to EUR1500 million ($1581.1 million). It prefers to take an equity stake.
How the Company Makes Moneynull

Marwyn Value Investors Financial Statement Overview

Summary
Strong balance sheet strength (near-zero leverage) and consistently positive operating cash flow support resilience. The main offset is highly volatile revenue/earnings across years, including a loss year and unusually inconsistent margins, which reduces confidence in durability.
Income Statement
72
Positive
Revenue and earnings are volatile, which is common in investment-driven models: revenue swung from a loss in 2020 to strong profits in 2021 and 2024. The latest annual period (2024) shows a sharp rebound with revenue up ~14% and very strong profitability, but prior years include a much smaller revenue base (2022–2023) and a negative year (2020), which reduces confidence in durability. Margins appear unusually high and inconsistent across years, suggesting results may be heavily influenced by non-recurring or fair-value type movements rather than steady fee-like income.
Balance Sheet
90
Very Positive
The balance sheet looks very conservative with minimal leverage: total debt is ~125k against equity of ~115m in 2024, keeping debt-to-equity near zero. Equity and total assets are large and generally stable over time, supporting resilience. Return on equity improved materially in strong years (notably 2021 and 2024) but was negative in 2020 and lower in 2022–2023, reflecting performance cyclicality rather than balance sheet stress.
Cash Flow
77
Positive
Cash generation is solid overall: operating cash flow remained positive each year (2020–2024) and was strong in 2021–2024. Free cash flow also stayed positive, though growth is choppy (down in 2022, up in 2023, down again in 2024). Cash flow comfortably covers reported earnings based on the provided relationship between free cash flow and net income, but the year-to-year swings suggest cash generation is not consistently compounding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Jun 2021
Income Statement
Total Revenue18.67M4.87M2.05M16.89M-1.20M
Gross Profit18.67M4.87M2.05M16.89M-1.20M
EBITDA18.67M-3.43K2.05M19.09M-1.20M
Net Income18.67M4.86M2.05M19.09M-1.20M
Balance Sheet
Total Assets115.03M101.38M102.42M105.40M97.73M
Cash, Cash Equivalents and Short-Term Investments140.04K133.99K129.15K128.55K128.61K
Total Debt125.00K125.00K125.00K125.00K125.00K
Total Liabilities140.04K133.99K125.00K125.00K125.00K
Stockholders Equity114.89M101.24M102.29M105.27M97.60M
Cash Flow
Free Cash Flow5.03M5.91M5.03M11.42M836.98K
Operating Cash Flow5.03M5.91M5.03M11.42M836.98K
Investing Cash Flow0.000.000.000.000.00
Financing Cash Flow-5.03M-5.91M-5.03M-11.42M-836.74K

Marwyn Value Investors Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
1.104.96%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
62
Neutral
£18.46M4.0216.48%-79.36%78.16%
48
Neutral
£1.45M-2.93-37.63%-100.66%84.15%
48
Neutral
£4.50M-1.85-12.33%
44
Neutral
£14.09M-19.81-21.85%
40
Underperform
$1.02M-0.04-96.59%93.69%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:MVI
Marwyn Value Investors
135.00
37.71
38.76%
GB:JADE
Jade Road Investments
0.43
-2.10
-83.18%
GB:TRUE
Braveheart Investment
1.85
-3.15
-63.00%
GB:MAFL
Mineral & Financial Investments
47.50
27.00
131.71%
GB:PRIM
Primorus Investments
3.60
0.00
0.00%
GB:450
Marwyn Acquisition Company PLC
2.10
0.00
0.00%

Marwyn Value Investors Corporate Events

Dividends
Marwyn Value Investors Declares Interim Dividend for Ordinary Shareholders
Positive
Jan 29, 2026

Marwyn Value Investors Limited has declared an interim dividend of 2.265p per ordinary share, to be paid on 27 February 2026 under its ordinary share distribution policy. The dividend will be settled electronically via CREST or BACS, with an ex-dividend date of 5 February and a record date of 6 February, and shareholders whose holdings are not CREST-settled are instructed to register bank details with the company’s registrar to ensure smooth, chequeless payment, underscoring the company’s continued commitment to cash returns for investors and fully electronic dividend settlement.

The most recent analyst rating on (GB:MVI) stock is a Buy with a £164.00 price target. To see the full list of analyst forecasts on Marwyn Value Investors stock, see the GB:MVI Stock Forecast page.

Other
Marwyn Director Moves Shares Between Broker Accounts With No Change in Holding
Neutral
Jan 8, 2026

Marwyn Value Investors Limited disclosed that independent non-executive director Peter Rioda has transferred 10,000 ordinary shares between his own broker accounts, a move that does not alter his overall beneficial holding in the company, which remains at 30,000 ordinary shares, or roughly 0.05% of voting rights. The company reiterated that its shares are not designed or promoted for retail investors, underscoring its focus on institutional and professional shareholders and signalling no change to its capital structure or governance from this internal share account transfer.

The most recent analyst rating on (GB:MVI) stock is a Buy with a £161.00 price target. To see the full list of analyst forecasts on Marwyn Value Investors stock, see the GB:MVI Stock Forecast page.

Regulatory Filings and Compliance
Marwyn Employees Increase Stake as CIO Corsellis’ Holding Rises to 12.3%
Positive
Dec 23, 2025

Marwyn Value Investors has disclosed that Marwyn employees have purchased 37,761 ordinary shares in the company from Marwyn Capital Management Limited at 135.69p per share, matching MCML’s original acquisition cost in October. Following the transaction, Chief Investment Officer James Corsellis and his wholly owned entity MCML together hold 6,933,872 ordinary shares, representing about 12.26% of the company’s voting rights, and while neither is formally classified as a PDMR, both the manager and the company have chosen to report the dealings to the market on a voluntary, PDMR-equivalent basis, underscoring a stance of heightened governance transparency for investors.

Other
Marwyn Director Peter Rioda Increases Stake with Additional Share Purchase
Positive
Dec 18, 2025

Marwyn Value Investors has disclosed that independent non-executive director Peter Rioda has increased his stake in the company by purchasing 10,000 ordinary shares at a price of £1.3807 per share. Following the transaction, executed on the London Stock Exchange, Rioda now holds 30,000 shares, representing approximately 0.05% of the company’s voting rights, a move that signals board-level confidence while remaining a relatively small position in the overall share capital.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026